ISRCTN81895822 https://doi.org/10.1186/ISRCTN81895822

Novel maintenance Immunosuppression with Controlled systemic Exposure

Submission date 27/01/2006	**Recruitment status** No longer recruiting	[_] Prospectively registered [_] Protocol [_] Statistical analysis plan [_] Results [_] Individual participant data [_] Record updated in last year
Registration date 27/01/2006	**Overall study status** Completed	
Last Edited 26/08/2009	**Condition category** Surgery	

Plain English summary of protocol
Not provided at time of registration

Contact information

Type(s)
Scientific

Contact name
Dr J.W. Fijter, de

Contact details
Leiden University Medical Center
Department of Nephrology
C3-P22
P.O. Box 9600
Leiden
Netherlands
2300 RC
+31 (0)71 5262169
jwdefijter@lumc.nl

Additional identifiers

Study information

Scientific Title
Added 26/08/09: Prospective, open label, randomised multicentre study to compare Area Under the Curve (AUC)-monitored withdrawal of either cyclosporin (Neoral®) or mycophenolate mofetil (MMF) (CellCept®) in stable renal transplant recipients on a triple regimen with cyclosporin, MMF and steroids.

Acronym
NICE

Study objectives
To compare the safety, efficacy, and impact on non-immune toxicity of AUC-controlled withdrawal of either cyclosporine or MMF in stable renal transplant recipients currently on a triple maintenance regimen with cyclosporin, MMF and steroids.

Ethics approval required
Old ethics approval format

Ethics approval(s)
Received from local medical ethics committee

Primary study design
Interventional

Study design
Multicentre randomised open label active controlled parallel group trial

Study type(s)
Treatment

Health condition(s) or problem(s) studied
Renal transplant

Interventions
Randomised, controlled, prospective multicentre study in stable renal transplant recipients, at least 6 months post-transplantation, who receive maintenance immunosuppressive treatment with cyclosporin bid, MMF 1 g bid, and steroids.
In eligible patients, systemic drug exposure (cyclosporin, MMF) will be measured by a 12-hour area under the time-blood concentration curve (AUC0-12) before randomisation to one of the three study arms.
Patients will be randomised 1:1:1 with stratification for the occurrence of previous acute rejection episodes.
Group A will continue on their current treatment regimen aiming at C2 levels of 700 ng/ml, (range: 600-800 ng/ml). In this group AUC-values will be blinded to the clinicians and evaluated retrospectively.
In group B (MMF withdrawal) cyclosporin will be dosed to reach the defined target AUC0-12 of 3250 ng.h/ml (range 3000-3500 ng.h/ml).
In group C (cyclosporin withdrawal) MMF will be given at a fixed dose of 1000 mg bid at the start of the study period. After cessation of the cyclosporine AUC will be measured to adjust the dose to reach the defined MPA-AUC0-12 target of 75 mg.h/ml (range 60-90 ng.h/ml). For safety reasons the minimal dose will be 500 mg bid.

Intervention Type
Drug

Phase
Not Specified

Drug/device/biological/vaccine name(s)
Cyclosporin (Neoral®), mycophenolate mofetil (MMF) (CellCept®)

Primary outcome(s)
1. Composite of Graft function
2. Incidence of acute rejection episodes
3. Graft and patient survival

Key secondary outcome(s)
1. Non-immune toxicity
2. Hypertension
3. Hyperlipedimia
4. Gout, uric acid
5. Magnesium
6. Nausea, dyspepsia, diarrhea
7. Anemia/Leukopenia/Thrombopenia
8. Infections (clinically defined)
9. Post-transplant lympho-proliferative disease
10. Malignancy

Completion date
01/01/2005

Eligibility

Key inclusion criteria
1. Patients, 18 years or older, on maintenance therapy with cyclosporin, MMF and steroids
2. Informed consent

Participant type(s)
Patient

Healthy volunteers allowed
No

Age group
Adult

Lower age limit
18 Years

Sex
All

Key exclusion criteria
1. Calculated creatinine clearance 20 ml/min
2. Multi-organ recipients
3. Patients with an (historic) PRA >60%
4. Vascular type rejection in the past
5. Patients with more than two acute rejection episodes in the past

6. Third renal transplant or more
7. Patients receiving other investigational drugs than MMF in combination with Neoral
8. Metastatic neoplasms, post-transplant lymphoproliferative disease

Date of first enrolment
01/01/2003

Date of final enrolment
01/01/2005

Locations

Countries of recruitment
Netherlands

Study participating centre
Leiden University Medical Center
Leiden
Netherlands
2300 RC

Sponsor information

Organisation
Leiden University Medical Center (LUMC) (Netherlands)

ROR
https://ror.org/05xvt9f17

Funder(s)

Funder type
Industry

Funder Name
Roche Nederland BV (Netherlands)

Funder Name
Novartis Pharma BV (Netherlands)

Results and Publications

Individual participant data (IPD) sharing plan

IPD sharing plan summary
Not provided at time of registration